GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG

GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG (96 tests ) - CVGQ0970

Enzyme-linked immunosorbent assay intended for the quantitative and qualitative detection of IgG antibodies against the spike protein of SARS-CoV-2 in human serum (venous, capillary) or plasma (citrate, heparin, EDTA). It is intended to aid in the diagnosis of patients suspected of having COVID-19 disease or asymptomatic infection with SARS-CoV-2, to monitor antibody levels during and after a COVID-19 disease, and to determine antibody levels before and after a COVID-19 vaccination.

  • Ready-to-use, color-coded reagents, and breakable strip plates
  • Standardized methods suitable for automated procedures
  • Qualitative and quantitative test with 5 standards
  • CE-IVD

Disease: COVID-19

Symptoms: It can present as an asymptomatic infection, a mild respiratory tract infection, or a severe pneumonia with respiratory failure and even death. The incubation period ranges from 2-14 days (5 days on average), and symptoms can include fever, cough, and shortness of breath

Mechanism of Infection: Primarily transmitted between people through respiratory droplets and contact routes

CVGQ0970
Product
Order no.
Format
Wishlist
GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG
Order no.CVGQ0970
Format96 tests
Add to wishlist

Documents

Name
Document type
Language
Format
Document
GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG (96 tests) - CVGQ0970 Rev. 01
IFUIFU
Language
Formatpdf
This document is only available for registered users. Login to reach it.
GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG
CoACoA
Language
Formatpdf
This document is only available for registered users. Login to reach it.
GSD NovaLisa® SARS-CoV-2 (COVID-19) quantitative IgG
MSDSMSDS
Language
Formatpdf
This document is only available for registered users. Login to reach it.